Elanco Animal Health (ELAN) Operating Margin (2017 - 2026)
Elanco Animal Health (ELAN) reported Operating Margin of 21.23% for Q1 2026, up 111.0% on a YoY basis from 10.06% in Q1 2025, and up 651.86% sequentially from 3.85% in Q4 2025.
Elanco Animal Health (ELAN) Operating Margin (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Operating Margin data on file, last reported at 21.23% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 111.0% year-over-year to 21.23%; the trailing twelve-month figure through Mar 2026 stood at 12.45% (up 2988.0% YoY), and the FY2025 full-year result was 11.83%, up 4596.0% from the prior year.
- Operating Margin advanced to 21.23% in Q1 2026, from 3.85% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 21.23% in Q1 2026 to a low of 148.31% in Q3 2023.
- A 5-year average of 31.67% and a median of 41.74% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin slumped 9802 bps in 2023 and jumped 15482 bps in 2024, its largest moves.
- Tracing ELAN's Operating Margin over 5 years: stood at 54.52% in 2022, then dropped by 14 bps to 62.13% in 2023, then advanced by 13 bps to 54.12% in 2024, then surged by 93 bps to 3.85% in 2025, then surged by 652 bps to 21.23% in 2026.
- Business Quant data shows ELAN's Operating Margin at 21.23% in Q1 2026, 3.85% in Q4 2025, and 12.49% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 8.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.23% |
| Dec 31, 2025 | -3.85% |
| Sep 30, 2025 | 12.49% |
| Jun 30, 2025 | 17.73% |
| Mar 31, 2025 | 20.12% |
| Dec 31, 2024 | -54.12% |
| Sep 30, 2024 | 6.50% |
| Jun 30, 2024 | -44.51% |
| Mar 31, 2024 | -41.74% |
| Dec 31, 2023 | -62.13% |
| Sep 30, 2023 | -148.31% |
| Jun 30, 2023 | -48.53% |
| Mar 31, 2023 | -30.71% |
| Dec 31, 2022 | -54.52% |
| Sep 30, 2022 | -50.29% |
| Jun 30, 2022 | -42.38% |
| Mar 31, 2022 | -35.40% |
| Dec 31, 2021 | -57.10% |
| Sep 30, 2021 | -55.88% |
| Jun 30, 2021 | -61.66% |